SITEMAP

• Products
  • Adacel®
  • Aubagio®
    • Aubagio vs Ofatumumab
  • Beyfortus®
    • International Recommendation
      • Nirsevimab International Recommendation
    • Conferences
      • Implementing Beyfortus successfully
      • Beyfortus®, an innovative immunization
      • Beyfortus in Action ECMMID
      • 2024 RSV International Congress - ESPID
      • 2024 RSV International Congress ECMMID
    • Real World Evidence
      • Implementing Beyfortus successfully (ES)
      • Implementing Beyfortus successfully (FR)
      • Implementing Beyfortus successfully (US)
      • Beyfortus in Action
      • Real World Evidence Impact of universal immunization with Nirsevimab
    • Clinical Experience
      • Nirsevimab : Clinical Experience
  • Cablivi®
    • HERCULES Study
      • Study Design
      • Hercules Summary
      • Platelet Count Normalization
      • aTTP-Related Events
      • Recurrences
      • Healthcare Resource Utilization
      • CABLIVI Safety Profile
    • aTTP Diagnosis and Treatment
      • Mechanism of Disease
      • CABLIVI Mechanism of Action
      • ISTH TTP Guidelines
    • Early Treatment Initiation
      • Real-World Evidence Studies
        • CNR-MAT Registry Study
        • Spanish
        • REACT-2020 and Aggregated Analysis
        • Italian
      • ISTH TTP Guidelines
      • CABLIVI-Specific Treatment Recommendation
      • Post-HERCULES
    • Delay in CABLIVI Start
      • Patient Outcomes
      • Active Disease
    • aTTP Sphere Digital Case Library
      • aTTP Sphere Digital Case Library - Kuwait
      • aTTP Sphere Digital Case Library - Qatar
      • TTP Patient Case Study in UAE
      • TTP Patient Case Study in KSA
      • TTP Patient Case Study in UAE
    • Cablivi® aTTP Patients Voice
  • Cerezyme®
  • Clexane®
    • Surgical Patients
    • Hemodialysis
  • Dupixent®
    • Atopic Dermatitis
    • Dupixent® COPD
    • Dupixent Asthma
    • Nasal Polyps
    • The Burden of AD through Dr. Ayman Alnaeem’s Expertise/eyes
    • Dr. Ayman Alnaeem’s Very First Dupixent Patient Experience
    • How Dupixent Changed Dr. Ayman AlNaeem’s Approach in AD Treatment
    • A Message to You from Dr. Ayman AlNaeem
    • The Burden of AD by Dr. Paula Nelson
    • Dr. Paula Nelson’s Very First Dupixent Patient Experience​
    • Dr. Paula’s insights on treating AD patients with Dupixent
  • Fabrazyme®
    • Quantifying the Effect of Fabrazyme
    • Canadian Fabry Disease Initiative
    • Long Term Renal Function
  • Lemtrada®
  • Myozyme®
  • Praluent®
    • It's Praluent of Course
      • Of Course
      • What is PRALUENT®?
      • Why choose PRALUENT®?
      • How to use PRALUENT®?
  • Sarclisa®
    • Sarclisa®
    • IMROZ Results
    • GMMG-HD7 Results
    • IKEMA Results
    • ICARIA-MM Results
    • Dosing & Administration
    • Mechanism of Action
  • Soliqua®
    • For a Peaceful Ramadan
    • Soliqua SoliD®
    • Soliqua Easy Start®
    • Soliqua Guidelines®
    • Soliqua Data Set®
    • Soliqua Simplicity®
    • Soliqua Safety®
    • Soliqua®
    • Post-GLP Podcast: needs of patients on GLP-1 RA with basal insulin
    • Soliqua Unmet Needs Video
    • Meet The Expert
    • Reimbursement
    • Limitations of Premixed Insulin
  • Toujeo®
    • Toujeo for a Peaceful Ramadan
    • Wall of Evidence
    • Toujeo T1DM
      • OneCare
      • Edition Junior
      • UltraFlexi-1
      • Type-1 Meta Analysis
      • Guidelines
    • Toujeo T2DM
      • Deliver-G
      • Guidelines
    • How to Start
    • Toujeo Innovation
      • Toujeo Upgrade to Win
    • Second generation basal insulin in advancing T2D therapy
    • Timely insulin initiation to limit disease progression
    • Meet the Expert
    • Always On
      • How to Start People with Diabetes to Toujeo
      • Bridging the Glycemic Gap- Timely Transition from OADs to Toujeo
      • Evolving Basal Insulin Therapy- From 1st Gen to 2nd Gen
      • The Kidney-Diabetes Connection- Clinical Use of Toujeo in Dual Diagnosis
      • Toujeo vs Degludec- Clinical Insights from the BRIGHT study for Insulin selection
      • Toujeo and GLP1s- Optimising Glycemic Control in Uncontrolled T2
      • New Findings on Toujeo® for T2D Management Following Dual GIP-GLP-1 RA Therapy
  • Xatral®
• Events
  • Cardiovascular
  • Diabetes
    • 2024
  • Neurological Disorders
    • 2022
      • What is Epilepsy
    • 2023
      • World Epilepsy Day Podcast Ep. 3
      • World Epilepsy Day Podcast Ep. 2
      • World Epilepsy Day Podcast Ep. 1
      • Sir Robin Murray updates us on Schizophrenia and it’s treatments
    • 2026
      • MS pulse - Tracking the hidden drivers of MS progression
  • Atopic Dermatitis
    • Type II Summit 2025
• Legal Notice
• Cookie Policy
• Privacy Policy
• Login
• Patient Support
  • Patient Support Articles
  • Atopic Dermatitis
  • Cardiovascular
    • 2022
      • Act now for ACS patients by Prof. Mohamed Balgeith
    • Are You Ready for 146? Achieving Optimal LDL-C Levels
    • Are You Ready for 556? Achieving Critical LDL-C Targets
    • Exploring the 556/146 Concept: Insights from Leading Experts
    • Understanding the 556/146 Concept: Insights from Leading Experts
    • 556/146 for Lipid Management after ACS
  • Diabetes
    • Tools and Resources
  • Rare Diseases
• Search
• Activate your Sanofi Account
• Oman Contact Details
• Events Calendar
  • My Lipid webinar 17 April
  • Dia-Tour Webinar: Smart Choices for Intensification
  • Insulin Initiation & Treatment Simplification for T2D - DiaTour
  • Smart Choices For Intensification & Treatment Simplification Options
  • Approach to lipid management in patients with Diabetes
• Science
  • Cutting Edge Science
  • Inspiration and Innovation
  • Acquired Thrombotic Thrombocytopenic Purpura (ATTP)
    • Cutting Edge Science
      • 2024
      • 2025
        • TTP Patient Case Study in Kuwait
      • 2025
        • Take a Closer Look at Heamophilia
        • It's Time to Look Beyond the Bleed
    • Hemophilia
  • Asthma
    • Cutting Edge Science
      • 2024
        • Severe Asthma Biomarker's
        • The Vital Role of Lung Function in Asthma Care
        • Sever Asthmatic patients with OCS
        • Asthma Clinical Remission: The Benchmarks for Eliminating Airway Inflammation and Symptoms
        • Fractional exhaled nitric oxide (Feno)
        • Airway Hyperresponsiveness
          in Asthma
        • ON-TREATMENT ASTHMA REMISSION: MOVING BEYOND CONTROL
      • 2025
        • FeNO Is a Clinically Useful Biomarker of Type 2 Inflammation in Pediatric Patients With Asthma
        • Mucus Plugging Is a Key Component of Remodeling
          in Asthma, Leading to Fixed Airway Obstruction
        • VESTIGE study
        • VESTIGE Trial Results: Dupilumab in Type 2 Asthma
        • Pediatric Management
        • Assessing Pediatric Lung Function
        • Understanding Airway Obstruction: The Role of Mucus Plugging in Asthmatic Disease
        • The Role of Mucus Plugging in Asthma and Its Clinical Burden
      • 2026
        • IL-4, IL-13, AND IL-5 ARE DRIVERS OF SYSTEMIC TYPE 2 INFLAMMATION
        • IL-4/IL-13 Dual Cytokine Signaling in Severe Asthma: Mechanistic Insights by Prof. Kenneth Chapman
        • LIBERTY ASTHMA QUEST Trial: Dupilumab Efficacy in Eosinophilic (≥500 cells/µL) and Allergic Asthma Subgroups
        • LIBERTY ASTHMA TRAVERSE Trial: Long-Term Safety and Efficacy of Dupilumab in Moderate-to-Severe Asthma
        • Dupilumab improves clinical outcomes in patients with severe asthma compared to other biologics
        • LIBERTY ASTHMA QUEST Trial: Dupilumab Evidence Summary in Moderate-to-Severe Uncontrolled Asthma
        • LIBERTY ASTHMA QUEST Trial: Dupilumab Efficacy in Type 2 Asthma Patients on High-Dose ICS
  • Atopic Dermatitis
  • Bullous Pemphigoid
    • 2025
      • What is Bullous Pemphigoid
      • Patient morbidity and mortality in BP
      • Pathophysiology of Bullous Pemphigoid
      • Treatments and challenges for bullous pemphigoid
      • Considerations for bullous pemphigoid management
      • Bullous Pemphigoid Burden of Disease and Diagnosis
    • 2026
      • Bullous Pemphigoid Mechanism of Disease Animation Storyboard
  • Cardiovascular
    • Atherothrombosis
      • Cutting Edge Science
        • Innovation
          • 2022
          • 2023
        • 2022
        • 2023
    • Dyslipidemia
    • Hypertension
    • Thrombosis
  • Chronic Obstructive Pulmonary Disease
  • Diabetes
    • Cutting Edge Science
      • Innovation
      • 2024
        • New Horizon in management of high-risk patients with Diabetes
        • Effective Treatment Simplification
  • Eosinophilic Esophagitis
  • Immune Thrombocytopenia ITP
    • Cutting Edge Science
      • 2025
        • Understanding ITP
        • What is ITP?
        • Living With ITP
        • Future of ITP
        • Interplay between the innate and adaptive immunity
        • Complex immune dysregulation impact on QoL
        • Rilzabrutinib a BTK inhibitor
        • The pathophysiology of ITP stems from complex immune dysregulation drives thrombocytopenia and inflammation
  • Multiple Myeloma
  • Multiple Sclerosis
    • Smoldering Neuroinflammation
    • MS Pulse Reels
  • Nasal Polyps
  • Neurological Disorders
    • Cutting Edge Science
  • Prurigo Nodularis
    • Cutting Edge Science
      • 2024
        • Practical Approach in Understanding PN Pathophysiology
        • The Pathophysiology of Prurigo Nodularis
  • Rare Diseases
    • Cutting Edge Science
      • Innovation
      • 2025
        • Every Moment Matters: Navigating Diagnosis of Fabry Disease
        • Safety and efficacy of Avalglucosidase Alfa versus Alglucosidase Alfa in patints with Late-Onset Pompe Disease (COMET): a phase 3, randomized, multicentral study results
        • Long-term Safety and Efficacy of Avalglucosidase Alfa IN Patients with Late-Onset Pompe Disease (NEO-EXT)
        • Understanding Gaucher Disease Type 3
      • 2026
        • Gaucher Mechanism of Disease
        • Gaucher Neurology Diagnosis Support
        • Gaucher Haematology Diagnosis Support
        • Gaucher Biochemistry Diagnosis Support
        • Fabry Disease in Cardiology Practice: From Red Flags to Diagnosis
        • Tolerability of Accelerated Agalsidase Beta Infusions in Fabry Disease: The SHORTEN Study Analysis
        • From Registry to Reality: Reduced Stroke Incidence with Agalsidase Beta in Fabry Disease
        • When Weakness Tells a Bigger Story
        • The Many Faces of Limb-Girdle Weakness
        • When the Heart, Kidneys, and Nerves Intersect
        • When Hematological Signs Lead the Diagnosis
        • The Enlarged Spleen Mystery
        • Renal Outcomes After Switching to Agalsidase Beta: A Single-Center Analysis
        • Pompe Care Podcast Series 2
        • What has been your experience with switching patients from alglucosidase alfa to avalglucosidase alfa?
        • What makes avalglucosidase alfa different from alglucosidase alfa in terms of clinical efficacy and patient outcomes?
        • How can you see changing the lives of patient starting taking Nexviazyme and if you can share from your experience couple of patient stories that realy impacted positively from staring the treatment for Pompe disease?
        • Thank You!
        • Pompe Care Podcast Series 3
        • What factors influence your decision to switch a patient from alglucosidase alfa to avalglucosidase alfa?
        • How has avalglucosidase alfa impacted the treatment paradigm for both infantile-onset and late-onset Pompe disease in your experience?
        • Have you observed any significant differences in treatment outcomes between these two therapies in your local practice?
        • What challenges do clinicians face in monitoring in disease progrission and response to therapy?
        • Structured Monitoring for Early Detection of Fabry Progression
    • Gaucher
      • Cutting Edge Science
    • Fabry
      • Cutting Edge Science
    • Pompe
      • Cutting Edge Science
    • ASMD
      • Cutting Edge Science
  • Vaccines
    • Influenza
    • RSV
      • Cutting Edge Science
        • 2023
          • RSV
          • All Infant Protection
          • RSV History
          • Burden of Disease
          • Rattle
        • 2024
          • RSV Burden in Infants
          • Saudi initiatives on Bronchiolitis Recommendations
        • 2025
          • RSV Burden in Jazan
          • Beyond High-Risk: Expanding RSV Protection for Newborns and Infants
          • New horizon of RSV lower respiratory tract disease LRTD in infants: Reflection on two seasons of prevention
          • Nirsevimab RWD Metanalysis
          • Kuwait taking the lead in RSV protection for all infants in the Middle east
          • Ensuring overall RSV prevention in every individual Dr. Alia Podcast
        • 2026
          • RSV Prevention Guidelines in UAE
          • Healthcare Utilization and Economic Burden of Pediatric Lower Respiratory Tract Infections Across Five Tertiary Hospitals in Saudi Arabia
    • Mass Gathering
      • Cutting Edge Science
        • 2025
          • Infectious Disease During Mass Gathering
  • Rhinology
    • Cutting Edge Science
      • Dupilumab for Patients with AFRS
• Register